Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.

Antimicrobial agents and chemotherapy - 1 Mar 2011

Liu Jia, Miller Michael D, Danovich Robert M, Vandergrift Nathan, Cai Fangping, Hicks Charles B, Hazuda Daria J, Gao Feng

Abstract excerpt

Raltegravir is highly efficacious in the treatment of HIV-1 infection. The prevalence and impact on virologic outcome of low-frequency resistant mutations among HIV-1-infected patients not previously treated with raltegravir have not been fully established. Samples from HIV treatment-experienced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Research and Treatment

Share to Mutation

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 21173185
DOI: 10.1128/AAC.01492-10
PMCID: PMC3067114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21173185-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.PMID 21173185Read ↗

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Semantic proximity Read ↗

Next-generation sequencing reveals major and minority HIV-1 drug resistance mutations in treatment-experienced individuals with virological failure.Semantic proximity Read ↗

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.Semantic proximity Read ↗

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.Semantic proximity Read ↗

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.Semantic proximity Read ↗

Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution.Semantic proximity Read ↗

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.Semantic proximity Read ↗

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencingSemantic proximity Read ↗

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy FailureSemantic proximity Read ↗

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.Semantic proximity Read ↗

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.Semantic proximity Read ↗

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.